Umoja Biopharma

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja’s CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111,… Read More

#Business & Investment #News

T cells
#Cancer research #CAR-T #Immunotherapy #Oncology #T cell activation #Umoja Biopharma

Positive early-stage results for in vivo CAR-T technology

Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More

#Cancer Research #News